182 related articles for article (PubMed ID: 16465406)
1. Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis.
Singh AS; Macpherson GR; Price DK; Schimel D; Figg WD
Oncol Rep; 2006 Mar; 15(3):519-24. PubMed ID: 16465406
[TBL] [Abstract][Full Text] [Related]
2. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM
Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872
[TBL] [Abstract][Full Text] [Related]
3. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
4. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M
Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
6. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
7. A metastatic human prostate cancer model using intraprostatic implantation of tumor produced by PC-3 neolacZ transfected cells.
Tsingotjidou AS; Ahluwalia R; Zhang X; Conrad H; Emmanouilides C
Int J Oncol; 2003 Dec; 23(6):1569-74. PubMed ID: 14612928
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
10. [Establishment of bone metastasis model of prostate cancer in nude mice by intratibia injection of human prostate cancer cell line Du145].
Luo Y; Zhang LL; Ning L; He DL; Fan JH; Hou HL
Zhonghua Nan Ke Xue; 2006 Feb; 12(2):133-6. PubMed ID: 16519149
[TBL] [Abstract][Full Text] [Related]
11. Development of an animal model for prostate cancer cell metastasis to adult human bone.
Tsingotjidou AS; Zotalis G; Jackson KR; Sawyers C; Puzas JE; Hicks DG; Reiter R; Lieberman JR
Anticancer Res; 2001; 21(2A):971-8. PubMed ID: 11396190
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
Quinn JE; Brown LG; Zhang J; Keller ET; Vessella RL; Corey E
Prostate Cancer Prostatic Dis; 2005; 8(3):253-9. PubMed ID: 15999121
[TBL] [Abstract][Full Text] [Related]
13. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Saad F; McKiernan J; Eastham J
Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive visualization of retinoblastoma growth and metastasis via bioluminescence imaging.
Ji X; Cheng L; Wei F; Li H; Wang M; Tian Y; Chen X; Wang Y; Wolf F; Li C; Huang Q
Invest Ophthalmol Vis Sci; 2009 Dec; 50(12):5544-51. PubMed ID: 19608529
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone.
Yonou H; Yokose T; Kamijo T; Kanomata N; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2001 Mar; 61(5):2177-82. PubMed ID: 11280783
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of metastatic potential in prostate carcinoma: an in vivo model.
Angelucci A; Gravina GL; Rucci N; Festuccia C; Muzi P; Vicentini C; Teti A; Bologna M
Int J Oncol; 2004 Dec; 25(6):1713-20. PubMed ID: 15547709
[TBL] [Abstract][Full Text] [Related]
19. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
20. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
Kim SJ; Uehara H; Yazici S; He J; Langley RR; Mathew P; Fan D; Fidler IJ
Cancer Res; 2005 May; 65(9):3707-15. PubMed ID: 15867366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
